Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?
New drug for cystic fibrosis does not significantly interfere with another drug that prevents organ rejection
Infant with cystic fibrosis has normal pancreas function and was missed by newborn screening after mom stayed on CFTR modulator therapy during pregnancy.
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC Study
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous
